Breast Oncologist at FDA, @FDAOncology Opinions are my own. Canadian/American hybrid 🇨🇦🇺🇸
Washington, DC
Joined February 2015
- Tweets182
- Following101
- Followers380
- Likes2.4K
Preeti Narayan, MD retweeted
Unfortunately, other obligations kept me and @JaniceTNBCmets from attending our favorite @abreastcancer session with the FDA, but nothing could keep us from at least saying hi to some of our favorite @FDAOncology people! @tmprowell #SABCS24
Preeti Narayan, MD retweeted
“Dose is the foundation of drug development. Having the wrong dose is like building a house on quicksand.”
@realrickpazdur, quoted by @pre_ryan at @NBCCStopBC’s #NBCCSummit.
Preeti Narayan, MD retweeted
Today’s #NBCCSummit panel includes @theNCI’s Larissa Korde, @pre_ryan, NBCC team leader Nicole Seagriff, and @QueensGlobalOnc’s Brooke Wilson about why oncology research should be designed to answer questions about outcomes and questions that matter for patients.
Mentioned this OCE initiative at @NBCCStopBC Advocate summit today at the outcomes that matter panel discussion, please post any ideas for pragmatic designs! @FDAOncology @drjennifergao @DrKNorsworthy @StevenClarkCunn @DrDonnaRivera
This Post is from an account that no longer exists. Learn more
Preeti Narayan, MD retweeted
✨Perfect day spending time with colleagues and friends ✨@FDAOncology
Preeti Narayan, MD retweeted
I want to say I appreciate @FDAOncology coming out from behind the curtain and discussing with patients and clinicians their thoughts & rationale around recent approvals. Great session, @SABCSSanAntonio 👏🏻
Preeti Narayan, MD retweeted
#SABCS23 Day 1 Highlights #CommunityOnc:
@FDAOncology Review on recent approvals
1. #CAPItello291
2. #EMERALD
3. #TDxD
4. Tumor Agnostic landscape
5. Post CDK4/6i HR+
@SABCSSanAntonio @VivekSubbiah @VKaklamani @JaniceTNBCmets #bcsm @DrSGraff @oreganruth
1/6
Preeti Narayan, MD retweeted
Great start at #SABCS23 with the session on New approval in metastatic #breastcancer
🔸Elacestrant
🔸T-DXd
🔸Capivasertib
Happening now at Hemisfair Ballroom 1-2
@SABCSSanAntonio
@OncoAlert
Important article for the oncology community on drug shortages and FDA's role, root causes for these shortages, and strategies to address -link is open access @OncoAlert
This Post is from an account that no longer exists. Learn more
Approved today, T-DXd for tx of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemo in the metastatic setting or developed disease recurrence during or within 6 months of adj chemo. Details below #bcsm
This Post is from an account that no longer exists. Learn more
Preeti Narayan, MD retweeted
This FDA Approval Summary gives you a look into the minds (or more importantly statistcal analysis) of the FDA breast team that reviewed #MONARCHE. Worth a read! @OncoAlert #bcsm
cc. @ErikaHamilton9
ascopubs.org/doi/abs/10.1200…
Preeti Narayan, MD retweeted
The iconic and beloved Betty White has died at 99.
Read all about her legendary legacy: thr.cm/vYZhSIW
So grateful to all the advocates out there for your continued work on improving clinical trials #bcsm #SABCS21 #patientadvocate
getting a shout out from Dr. @tmprowell at the @abreastcancer FDA-#advocate "lunch" for my being vocal about the need for decentralized clinical trials and how it has influenced the @FDAOncology is making me 🥲 and motivating me to keep being an #advocate #SABCS21
Preeti Narayan, MD retweeted
There’s a cultural perception in drug development that enrolling a diverse, heterogeneous patient cohort can be “risky” for detecting drug effects—a perception that needs to go away, said @LolaFashoyinAje.
cancerletter.com/conversatio…
Preeti Narayan, MD retweeted
Today, FDA approved the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy. go.usa.gov/x6CVW
Preeti Narayan, MD retweeted
In this edition of #FirstPerson, we feature Richard Pazdur, MD (@realrickpazdur), founding director of the @FDAOncology Center of Excellence, who has long spearheaded major initiatives to improve oncology drug development. Read more about his impact: acsjournals.onlinelibrary.wi…
Regular approval for sacituzumab based on confirmatory ASCENT trial
▶️ Indication expanded to "for patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease" ⬇️
This Post is from an account that no longer exists. Learn more